CombiGene AB (publ) reported earnings results for the fourth quarter ended December 31, 2021. For the fourth quarter, the company reported sales was SEK 84.04 million. Net income was SEK 57.45 million compared to net loss of SEK 10.96 million a year ago.

Basic earnings per share from continuing operations was SEK 2.9 compared to basic loss per share from continuing operations of SEK 1.22 a year ago. Diluted earnings per share from continuing operations was SEK 2.9 compared to diluted loss per share from continuing operations of SEK 1.22 a year ago.